SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / Medical3-DIMENSIONAL PHARMACEUTICALS (DDDP)


Previous 10 Next 10 
To: Dave Gore who wrote (47)1/4/2002 4:31:07 PM
From: scaram(o)uche
   of 146
 
I think that most who contribute to this thread will hold it long-term. I will. OTOH, there's a lot of trader in many of us as well.

DDDP is a component of both the "2000" and "2001" portfolios, and the company -- together with several additional small caps -- is also followed here.......

Subject 33643

They present at 8 a.m. on Wednesday at H&Q. I and several other SI biofreaks will be there.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: scaram(o)uche who wrote (48)1/4/2002 4:51:07 PM
From: Dave Gore
   of 146
 
Thanks for the feedback, Richard. Look forward to your report from H&Q.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Dave Gore who wrote (49)1/4/2002 5:09:15 PM
From: scaram(o)uche
   of 146
 
>> Look forward to your report from H&Q. <<

You do? Why, have you got your checkbook out?

Amazing.

You have free access, at SI, to the best biotech analysis that you'll find anywhere, at any price. Expect it, and you'll get zip.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: scaram(o)uche who wrote (50)1/4/2002 7:04:30 PM
From: Dave Gore
   of 146
 
Richard, I provide a lot of free services and analysis myself, and have for several years here at SI. Check out my thread sometime. It was leading the HOT TOPIC list for about 5 days in a row recently, and I put a lot of work into it.

Message 16862879

I am quite respected on SI and thought my comment was pretty innocuous and friendly. I didn't realize I was hitting such a nerve and btw, I wasn't expecting anything. I just assumed that you would mention something on the thread. If you care not too, or don't plan too, no big deal, guy.

Somehow we'll all survive with our 5-10 points we many made in SEBL this week, or 2+ points in CSCO, 3.5 points in MSFT, 2.5 points in SANM, 2+ points in BMC, 3+ points in GD, and 40% in CLAC. Oh and that is on top of the 2-3 points in HCR, MHP, and others the week before. Those more than offset our few losses that we nipped off quickly.

Sorry to be so direct, but it's been a long week and I don't take kindly to your reply which makes you sound like a whining egomaniac.

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: Dave Gore who wrote (51)1/4/2002 7:36:18 PM
From: scaram(o)uche
   of 146
 
>> It was leading the HOT TOPIC list for about 5 days in a row recently <<

Oh, my!! I didn't know!! Please accept my apologies for being so rude. And please forgive the whining.

Bye, bye.

Share RecommendKeepReplyMark as Last Read


To: Dave Gore who wrote (51)1/5/2002 12:04:33 PM
From: scaram(o)uche
   of 146
 
>> I just assumed <<

I see. You weren't expecting anything, you were just assuming something. Or you weren't assuming anything, you were just...... um......

Sorry, I got into a bit of circular double talk there. For some reason, I fell into circular BS.

Experience indicates that promotional spam artists shouldn't assume and/or expect that they're going to get anything from SI's biofreaks.

Regarding my attitude (whining?... you don't recognize open contempt?)..... I had just come from the Yahoo DDDP thread where you post as SeattleGuru. I opened the "2002 Contest" thread to find your BS promotional crap there (bolded, no less!) as well. Fortunately, Michael promptly hopped all over it.

Then I opened this thread and found you here. I politely answered your question -- given that there wasn't any promotional garbage -- against my best judgement.

I don't buy into the spam crap of those who try to generate a trading profit. You can try to assemble a gaggle of new-era Tokyo Joe disciples if you like, but you're sure as heck not going to use some of our threads to do it, Mr. self-proclaimed Guru.

Message 16863146
messages.yahoo.com

I hope that this clarifies my bad attitude.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: scaram(o)uche who wrote (53)1/8/2002 8:19:45 PM
From: Miljenko Zuanic
   of 146
 
2.4 m shares seem plenty, but SKB is taking good portion of risk in this deal.

Tuesday January 8, 8:02 am Eastern Time
Press Release
SOURCE: 3-Dimensional Pharmaceuticals, Inc.
3-Dimensional Pharmaceuticals Licenses TPO Peptide from GlaxoSmithKline
YARDLEY, Pa., Jan. 8 /PRNewswire/ -- 3-Dimensional Pharmaceuticals, Inc. (Nasdaq: DDDP - news; 3DP) today announced that the Company has entered into an exclusive licensing agreement with GlaxoSmithKline (GSK), giving it worldwide development, marketing and distribution rights to GSK's pre-IND compound GW 395058 for the prevention and treatment of thrombocytopenia, or low blood platelet count. GW 395058 is a pegylated synthetic thrombopoietin (TPO) mimetic peptide that stimulates the human body to increase its production of blood platelets, which are responsible for regulating the clotting process.

3DP's initial development focus will be on chemotherapy induced thrombocytopenia because of the frequency with which cancer patients undergoing certain chemotherapy regimens experience thrombocytopenia. The condition can prolong blood clotting times, increase the risk of bruising, and, in extreme cases, prompt internal hemorrhaging. These side effects frequently disrupt cancer treatment protocols, including delays in, and the lowering of chemotherapy dosing regimens.

``Thrombocytopenia is the unfortunate consequence of a wide range of diseases and disease treatments,'' said David U'Prichard, Ph.D., Chief Executive Officer of 3DP. ``We see GW 395058 as an important addition to our rapidly growing pipeline of treatment and supportive therapies for cancer. In addition, we believe there could be significant upside potential from the development of GW 395058 for various non-cancer related indications. We are pleased that we have been able to successfully negotiate this transaction with GSK's Genetics & Discovery Ventures Team.''

The current standard of care for thrombocytopenia is a platelet transfusion; however, there are a number of potentially negative side effects associated with this procedure. About one third of the two million platelet transfusions administered each year in the United States are given to cancer patients, while the remainder are given to patients with a variety of conditions including coronary bypass and hepatic surgery, HIV/AIDS, hepatitis B and C, and idiopathic thrombocytopenia purpura.

Under the terms of the agreement, all payments by 3DP to GSK will be made in the form of 3DP stock. 3DP will make an initial upfront payment of 500,000 shares and future milestone payments based on achievement of certain key development and regulatory events. In total, 3DP may provide 2.4 million shares to GSK.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Miljenko Zuanic who wrote (54)1/9/2002 2:19:31 AM
From: scaram(o)uche
   of 146
 
Wo.

Geeze, unexpected wrinkle. It says *all* payments, suggesting no royalties? If so, this looks like a big vote of confidence in the Centocor and JNJ-independent-of-Centocor activities?

First blush, I like this. I forget..... why did the Amgen and ZymoGenetics projects fade? Too tired to look up the answer. Back to participation on Friday.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: scaram(o)uche who wrote (55)1/9/2002 11:59:17 AM
From: keokalani'nui
   of 146
 
It will be interesting (for me) to watch the race between 3DP's peg-mimetic and alxn's TPO Mab agonist in as much as each company promises to be in the clinic this year and they are totally different approaches. BTW, I thought I heard 3DP say its candidate would be admin bolus. Hope these programs will be of interest to you guys so maybe I can learn while you earn.

Wilder (now a 3dp shareholder too)

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: keokalani'nui who wrote (56)1/10/2002 10:09:48 PM
From: Miljenko Zuanic
   of 146
 
<<(now a 3dp shareholder too)>>

Welcome!

Somehow 3DP remained me on VRTX-NBIX combo. Hope they can select only the good part of this combination.

Miljenko

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10